RUFINAMIDE IN THE TREATMENT OF LENNOX–GASTAUT SYNDROME: REVIEW OF FOREIGN LITERATURE
https://doi.org/10.17650/2073-8803-2015-10-2-32-37
Abstract
Lennox–Gastaut syndrome (LGS) is childhood-onset epileptic encephalopathy characterized by frequent polymorphic seizures, including tonic, axial, obvious cognitive impairments, interictal EEG slow spike-wave discharges with fast activity at 10–20 Hz, which are frequently associated with tonic seizures and resistance to therapy. Treatment for LG presents great challenges due to the fact that its clinical picture is characterized by a concurrence of a few types of seizures and their resistance to drug therapy. In this connection, there are great expectations for the design of new antiepileptic drugs that have radically other mechanisms of action and must aim specially for the treatment of this severe form of epilepsy. The authors review the foreign literature on the use of the new in Russia antiepileptic drug rufinamide (Inovelon) registered just for the treatment of adult patients and in children who are at least 4 years old. Rufinamide (Inovelon) was registered in Russia in January 2015 as adjunctive treatment of seizures associated with LGS in patients from 4 years of age. The paper describes the mechanism of action, pharmacokinetics, efficacy, and tolerability of rufinamide in LGS. Numerous trials have demonstrated the efficacy and good tolerability of rufinamide in the treatment of LGS.
About the Authors
K. Yu. Mukhin
Svt. Luka’s Institute of Child Neurology and Epilepsy, 6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396, Russia
Russian Federation
Russian Federation
O. A. Pylaeva
Svt. Luka’s Institute of Child Neurology and Epilepsy, 6 Svetlaya St., Puchkovo, Troitsk, Moscow, 143396, Russia
Russian Federation
Russian Federation
References
1. Инструкция по медицинскому применению препарата Иновелон®. РУ-ЛП-002841 [Guidelines for medical use of Inovelon®. RU-LP-002841 (In Russ.)].
2. Aicardi J., Levy Gomes A. The Lennox– Gastaut syndrome: clinical and electroencephalographic features. In: The Lennox–Gastaut syndrome. E. Niedermeyer, R. Degen (еds.). N.-Y., 1988. Pр. 25–46.
3. Albini M., Morano A., Fanella M. et al. Effectiveness of rufinamide in the treatment of idiopathic generalized epilepsy with atypical evolution: case report and review of the literature. Clin EEG Neurosci 2014.
4. Alsaad A.M., Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol 2014;78(6):1264–71.
5. Beaumanoir A., Dravet Ch. The Lennox– Gastaut syndrome. In: Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. J. Roger, M. Bureau, Ch. Dravet et al. (еds.). John Libbey, 1992. Pр. 307–12.
6. Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90.
7. Genton P., Dravet Ch. The Lennox–Gastaut syndrome. In: Comprehensive еpileptology. 2nd ed. J. Engel, T.A. Pedley (еds.). Philadelphia: Lippincott–Raven, 2007. Pр. 2417–27.
8. Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70(21):1950–8.
9. Grosso S., Coppola G., Dontin S.D. et al. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies. Eur J Paediatr Neurol 2014;18(5):641–5.
10. Guerrini R., Marini C. Epileptic еncephalopathies. In: Epilepsy and еpileptic seizures. S. Shorvon, R. Guerrini, M. Cook, S. Lhatoo (еds.). UK: Oxford University Press, 2013. Pр. 177–80.
11. Hsieh D.T., Thiele E.A. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord 2013;6(3):189–98.
12. Ide M., Kato T., Nakata M. et al. A granulocytosis associated with rufinamide: A case report. Brain Dev 2015.
13. Kayani S., Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J Cent Nerv Syst Dis 2012;4:51–63.
14. Kessler S.K., McCarthy A., Cnaan A., Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox–Gastaut syndrome. Epilepsy Res 2015;112:18–26.
15. Kluger G., Bauer B. Role of rufinamide in the management of Lennox–Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007;3(1): 3–11.
16. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010;122(3):202–8.
17. Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with Lennox–Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg 2013;115(7):926–9.
18. Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox–Gastaut syndrome. Epilepsia 2014; 55 Suppl 4:10–20.
19. Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8.
20. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res 2014;108(9):1627–36.
21. Verrotti A., Loiacono G., Rossi A. et al. Successful treatment of refractory seizures with rufinamide in children with schizencephaly: report of 3 cases. J Child Neurol 2014.
22. Wheless J.W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies. J Child Neurol 2009;24(12):1520–5.
23. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox–Gastaut syndrome: A comprehensive overview. Paediatric Drugs 2011;13(2):97–106.
Review
For citations:
Mukhin K.Yu., Pylaeva O.A. RUFINAMIDE IN THE TREATMENT OF LENNOX–GASTAUT SYNDROME: REVIEW OF FOREIGN LITERATURE. Russian Journal of Child Neurology. 2015;10(2):32-37. (In Russ.) https://doi.org/10.17650/2073-8803-2015-10-2-32-37
Views:
4313
Email this article 